An interventional study of SELF-BREATHE in Chronic Obstructive Pulmonary Disease, Bronchiectasis and Interstitial Lung Disease, sponsored by King's College Hospital NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2025-06-13.
Sponsored by King's College Hospital NHS Trust · Not applicable, Interventional, and Treatment
Among 620 studies in Pulmonary Disease, Chronic Obstructive with a site in United Kingdom — 60 open to participants now, 75 under way, 10 of them phase 3. Pulmonary Disease, Chronic Obstructive · United Kingdom.
Among the 620 studies in Pulmonary Disease, Chronic Obstructive with a site in United Kingdom, this one is the 131st largest by planned enrollment of the 465 interventional ones that give a count, is one of 18 that started in 2024, is one of 122 with no phase, reaches primary completion later than 60 of the 74 other live ones, and was the 573rd registered.
5,521 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →60 of the 620 studies in Pulmonary Disease, Chronic Obstructive with a site in United Kingdom are open now. Recruiting first, the newest first:
Richmond Research Institute · Sites in United Kingdom
Ages 18+
Hoffmann-La Roche · Sites in United Kingdom
Ages 18–80 · Healthy volunteers
AeroRx Therapeutics Inc. · Sites in United Kingdom
Ages 40–75
Liverpool Heart and Chest Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18–110
University Hospital Southampton NHS Foundation Trust · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 18 Years to 110 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
620 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 102 · Phase 2 108 · Phase 3 100 · Phase 4 50
First in 2000; this study’s year is marked. 18 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 246 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 80 across the 465 interventional studies, 104 across the 155 observational. Of the 476 that completed or were terminated, 148 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
341 of 620 have an industry lead sponsor. The 10 most frequent:
King's College Hospital NHS Trust is the lead sponsor of 171 studies on the registry; 56 are open to participants now.
King's College Hospital NHS Trust has 5 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
26 of the studies in Pulmonary Disease, Chronic Obstructive with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT06154837GlaxoSmithKlineA Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease | 2026-12-16 |
| NCT07102823Medical University of GrazClinical Registry for the Characterization of the 'Pulmonary Vascular Phenotype' in Patients With Chronic Obstructive Pulmonary Disease | 2026-12-30 |
| NCT04236726Guy's and St Thomas' NHS Foundation TrustInvestigating Health Related Quality of Life in Patients With Chronic Respiratory Failure | 2026-12-31 |
Add all 26 to your calendar (.ics) → With an account.
Among the 620 studies in Pulmonary Disease, Chronic Obstructive with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background:
Some health conditions make breathing difficult and uncomfortable. When this happens every day, it is called chronic breathlessness. Over 3 million people living with heart and lung disease have chronic breathlessness in the UK.
Breathlessness is very difficult for patients themselves and their families, resulting in disability and feelings of fear, distress, and isolation. Due a to lack of supportive breathlessness services many patients frequently attend hospital Accident and Emergency (A\&E) departments seeking help.
Given the on-going challenges faced by the National Health Service (NHS) in the United Kingdom, such as long waiting times, staff shortages, increased demand for services because of the COVID-19 pandemic, there is an urgent need to develop new ways to support those living with chronic breathlessness. One potential solution is to offer support online, as it is estimated that in the UK, 7 out of every 10 people with chronic breathlessness are internet users.
With the help of patients and NIHR funding the research team lead by Dr Charles Reilly, developed an online breathlessness supportive website called SELF-BREATHE. SELF-BREATHE provides information and self-management tools such as breathing exercises, that patients can do at home themselves.
SELF-BREATHE has been tested as part of its development. SELF-BREATHE is acceptable and valued by patients. But what is unknown is whether SELF-BREATHE improves patients' breathlessness and their life? This is the question this research seeks to answer.
Aims
Methods
The research team are undertaking a randomised controlled trial. For this, 246 people living with chronic breathlessness will be recruited in to this study. Each person will be randomly chosen by a computer to continue with their usual care or their usual care plus access to SELF-BREATHE. All study participants will complete questionnaires at the start of the study, thereafter at seven and twelve weeks after randomisation.
These questionnaires will ask patients about 1) their breathlessness and its effect on their life and 2) planned and unplanned hospital visits. At the end of the study, we will compare answers to these questionnaires between the two groups at seven and 12 weeks.
This will tell if SELF-BREATHE improved patients' breathlessness and reduced their need for unplanned hospital visits e.g., A\&E attendances due to breathlessness.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SELF-BREATHE + usual NHS care (Intervention)
Other: SELF-BREATHE
Participants randomised to the control group continue with usual NHS care, as was available to them prior to entry into the trial
SELF-BREATHE is on online supportive self - management intervention for individuals living with chronic breathlessness due to respiratory disease. SELF-BREATHE provides user with educational resources about breathlessness and self - management techniques such as breathing exercises, goal setting which aims to help with their breathlessness.
Numerical Rating Scale (NRS) Worst Breathlessness
The primary outcome is patient rated intensity of worst breathlessness over the previous 24 hours, using a validated 11-point (0-10) numerical rating scale (NRS), where 0 = no breathlessness, and 10 = worst imaginable breathlessness (Patient self-reported out-come measure)
Time frame: previous 24 hours
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Feb 2028, 43 months after the start.
Of 1,095 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 43 months is above that.
Counting every sponsor, half of 1,182 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
King's College Hospital NHS Trust →